GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Citalopram tablets (adults)

Local official-label summaryBase record retrieved 2026-09-05See the evidence for this drug2 sources available - open source summaries, references and comparisons

Celexa

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

Citalopram tablets (adults) - selected U.S. labeling

Product / population
Adults with major depressive disorder; oral citalopram hydrobromide tablets only. This page does not cover the 30 mg capsule or oral-drop conversion.
Renal measure
CrCl in mL/min for the severe-renal data boundary; no numeric adjustment algorithm.
Labeled basic dosing

Start 20 mg orally once daily. When needed, increase after at least one week; maximum 40 mg/day. Limit to 20 mg/day in patients older than 60, hepatic impairment, CYP2C19 poor metabolizers, or those taking CYP2C19 inhibitors.

Renal information and dialysis

Mild or moderate renal impairment: no dose change is recommended. Pharmacokinetic data are unavailable at CrCl below 20 mL/min. This label supplies no numeric severe-renal or dialysis dose.

Selected warnings and limits

Assess QT-prolongation risk and electrolytes; monitor for suicidality and serotonin syndrome. Review MAOI and other interacting drugs before treatment.

Source revision: Label revision date not separately recorded; retrieval date is not the revision date. | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c133fc77-6c8a-d2b1-e053-2995a90ab5f7

Scope: Selected dosing/renal sections read; concise local summary, not full prescribing information. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Official product label

Citalopram tablets (adults) - selected U.S. labeling

Adults with major depressive disorder; oral citalopram hydrobromide tablets only. This page does not cover the 30 mg capsule or oral-drop conversion.

Renal method: CrCl in mL/min for the severe-renal data boundary; no numeric adjustment algorithm.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
Handbook

Renal Drug Handbook, fifth edition - Citalopram tablets (adults)

Historical renal/RRT cross-check for the named ingredient; not a current U.S. prescribing instruction.

Renal method: Book table headings say GFR (mL/min); the preface states adjustment information is based on Cockcroft-Gault CrCl, not indexed eGFR. Do not substitute methods.
Retrieved: 2026-09-05

Read local renal result

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Official source

Citalopram tablets (adults) - selected U.S. labeling

Adults with major depressive disorder; oral citalopram hydrobromide tablets only. This page does not cover the 30 mg capsule or oral-drop conversion.

Method: CrCl in mL/min for the severe-renal data boundary; no numeric adjustment algorithm.

Renal information and dialysisRead this complete source summary
Handbook source

Renal Drug Handbook, fifth edition - Citalopram tablets (adults)

Historical renal/RRT cross-check for the named ingredient; not a current U.S. prescribing instruction.

Method: Book table headings say GFR (mL/min); the preface states adjustment information is based on Cockcroft-Gault CrCl, not indexed eGFR. Do not substitute methods.

Historical renal and dialysis observationsRead this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeCitalopram tablets (adults) - selected U.S. labelingRenal Drug Handbook, fifth edition - Citalopram tablets (adults)
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c133fc77-6c8a-d2b1-e053-2995a90ab5f7

Product and population scope

Adults with major depressive disorder; oral citalopram hydrobromide tablets only. This page does not cover the 30 mg capsule or oral-drop conversion.

RDM31-citalopram-tablets-scope · Source section: Editorial scope tied to selected U.S. labelRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Citalopram tablets (adults) - selected U.S. labeling

Open original reference

Open / share this exact local source

U.S. product labeling / DailyMed · Adults with major depressive disorder; oral citalopram hydrobromide tablets only. This page does not cover the 30 mg capsule or oral-drop conversion.

Renal method: CrCl in mL/min for the severe-renal data boundary; no numeric adjustment algorithm.
Source date: Label revision date not separately recorded; retrieval date is not the revision date.
Retrieved: 2026-09-05

Selected dosing/renal sections read; concise local summary, not full prescribing information.

Labeled basic dosing

Start 20 mg orally once daily. When needed, increase after at least one week; maximum 40 mg/day. Limit to 20 mg/day in patients older than 60, hepatic impairment, CYP2C19 poor metabolizers, or those taking CYP2C19 inhibitors.

RDM31-citalopram-tablets-label-dose · Source locator: 2.1, 2.3, 2.4

Renal information and dialysis

Mild or moderate renal impairment: no dose change is recommended. Pharmacokinetic data are unavailable at CrCl below 20 mL/min. This label supplies no numeric severe-renal or dialysis dose.

RDM31-citalopram-tablets-label-renal · Source locator: 12.3: Patients with Renal Impairment

Selected warnings and limits

Assess QT-prolongation risk and electrolytes; monitor for suicidality and serotonin syndrome. Review MAOI and other interacting drugs before treatment.

RDM31-citalopram-tablets-label-limits · Source locator: Boxed warning; 4; 5.1-5.3

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c133fc77-6c8a-d2b1-e053-2995a90ab5f7
Retrieved
2026-09-05
DailyMed Set ID
c133fc77-6c8a-d2b1-e053-2995a90ab5f7
Renal-function method
CrCl in mL/min for the severe-renal data boundary; no numeric adjustment algorithm.
Source date/version
Label revision date not separately recorded; retrieval date is not the revision date.
Hash meaning
SHA-256 identifies this local summary, not original SPL XML or label PDF.
Local summary SHA-256
6a3b7dbf3709f4abb22e3f904bba7b1aff97990f2f0e09fa5566b08fec6b6c2a
Separate handbook layer

Renal Drug Handbook cross-check

Handbook

Renal Drug Handbook, fifth edition - Citalopram tablets (adults)

Open / share this exact local source

UK Renal Pharmacy Group / CRC Press · Historical renal/RRT cross-check for the named ingredient; not a current U.S. prescribing instruction.

Renal method: Book table headings say GFR (mL/min); the preface states adjustment information is based on Cockcroft-Gault CrCl, not indexed eGFR. Do not substitute methods.
Source date: Fifth edition, 2019
Retrieved: 2026-09-05

Historical source, separately displayed. Renal tables were read with page-image inspection.

Historical renal and dialysis observations

The historical table retains ordinary dosing at 20-50 and 10-20 mL/min; below 10 it adds caution. Hemodialysis and high-flux/HDF removal are described as absent; peritoneal and continuous removal are considered unlikely. The subsequent comments note limited severe-renal experience.

RDM31-citalopram-tablets-book · Source locator: Dose in renal impairment; renal replacement therapies; Other information

Source-specific limits

The book supplies practice advice beyond the label's severe-renal evidence. Do not interpret it as a label-proven dialysis dose.

Source identity and provenance
Retrieved
2026-09-05
Handbook page
Printed page(s) 220-221; PDF page(s) 239,240
Renal-function method
Book table headings say GFR (mL/min); the preface states adjustment information is based on Cockcroft-Gault CrCl, not indexed eGFR. Do not substitute methods.
Source date/version
Fifth edition, 2019
U.S. product identity basis
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c133fc77-6c8a-d2b1-e053-2995a90ab5f7
Hash meaning
SHA-256 identifies the local paraphrase; the source PDF is not redistributed.
Local summary SHA-256
0139a1fd3960a645657af773aee53e3b50908a08c98d229041e8c369a480b9e1

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 0 RX List, 0 professional, 1 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c133fc77-6c8a-d2b1-e053-2995a90ab5f7
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
d8559fd52e04e584a1228c774e8b29dcc6d150b8238620162a13e2164788c684
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report